Under a tenth of individuals who could benefit from GLP-1 drugs like Wegovy can access them, states the World Health Organization as it issues its first advice on the drugs.
Given in excess of 1,000,000,000 individuals worldwide currently obese, it is advocating for broader and more equitable availability to GLP-1 medication.
Based on projections, in excess of 2,000,000,000 will be obese by 2030 without intervention.
"Our latest guidelines acknowledges that excess weight is a long-term condition that can be treated with comprehensive and ongoing care," said the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and logistical bottlenecks are major obstacles to universal availability to the treatments that can assist patients in reducing considerable body mass, explains the organization.
GLP-1 Therapy Shortage
Even under the present best projected scenario, the production of GLP-1 therapies could only cover approximately 100 million people – under 10% of those who need them, according to the health organization.
The advice encourages countries and companies to expand availability, through approaches like patent sharing.
A patent on a key compound – the primary component of a leading brand – is set to lapse in multiple countries in 2026.
The Way Weight-Loss Injections Operate
GLP-1 drugs mimick a biological compound to delay gastric emptying, curb appetite and increase the sense of being full so people eat less.
Individuals commonly start to lose weight after several weeks of starting on the weekly injections.
Studies indicates users may regain a significant portion after a year of halting the medication, because their normal appetite come back.
To be overweight or obese increases your chance for developing medical conditions, including diabetes, cardiovascular issues, brain attack, and certain malignancies.
Obesity affects individuals in every country and was responsible for 3.7 million fatalities worldwide in 2024, per the WHO.
